CXCR4 and neoplasm: Although plerixafor is approved for hematopoietic stem cell mobilization in lymphoma, multiple preclinical studies in other hematologic and solid tumors, including leukemias and diffuse large B-cell lymphoma, have shown that CXCR4 blockade can synergize with chemotherapy, sensitize tumor cells, and modulate the altered tumor microenvironment (82).